Fmr LLC Buys 86,455 Shares of 10x Genomics, Inc. (NASDAQ:TXG)

FMR LLC raised its stake in 10x Genomics, Inc. (NASDAQ:TXG - Free Report) by 0.6% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 13,454,434 shares of the company's stock after buying an additional 86,455 shares during the period. FMR LLC owned about 11.11% of 10x Genomics worth $193,206,000 as of its most recent SEC filing.

A number of other institutional investors have also recently made changes to their positions in the stock. Signaturefd LLC lifted its stake in shares of 10x Genomics by 424.6% in the 4th quarter. Signaturefd LLC now owns 1,794 shares of the company's stock valued at $26,000 after purchasing an additional 1,452 shares during the period. Blue Trust Inc. lifted its stake in 10x Genomics by 73.1% in the fourth quarter. Blue Trust Inc. now owns 3,075 shares of the company's stock valued at $44,000 after buying an additional 1,299 shares during the period. Sound Income Strategies LLC boosted its holdings in shares of 10x Genomics by 65.2% during the 4th quarter. Sound Income Strategies LLC now owns 3,370 shares of the company's stock worth $48,000 after buying an additional 1,330 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. acquired a new stake in shares of 10x Genomics during the 4th quarter worth approximately $52,000. Finally, SRS Capital Advisors Inc. increased its stake in shares of 10x Genomics by 817.4% in the 4th quarter. SRS Capital Advisors Inc. now owns 4,853 shares of the company's stock valued at $70,000 after acquiring an additional 4,324 shares in the last quarter. Institutional investors own 84.68% of the company's stock.

Insider Transactions at 10x Genomics

In other 10x Genomics news, insider Benjamin J. Hindson sold 4,573 shares of the stock in a transaction dated Monday, February 24th. The shares were sold at an average price of $11.07, for a total transaction of $50,623.11. Following the completion of the transaction, the insider now owns 335,324 shares in the company, valued at $3,712,036.68. This trade represents a 1.35 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Alan Mateo purchased 40,000 shares of the stock in a transaction dated Friday, February 21st. The stock was acquired at an average cost of $11.14 per share, for a total transaction of $445,600.00. Following the transaction, the director now owns 61,691 shares of the company's stock, valued at approximately $687,237.74. This trade represents a 184.41 % increase in their ownership of the stock. The disclosure for this purchase can be found here. 10.03% of the stock is currently owned by company insiders.

Remove Ads

Analyst Ratings Changes

Several research analysts recently issued reports on the stock. JPMorgan Chase & Co. cut their target price on shares of 10x Genomics from $14.00 to $12.00 and set a "neutral" rating on the stock in a research note on Thursday, February 13th. UBS Group cut their price objective on shares of 10x Genomics from $20.00 to $14.00 and set a "neutral" rating on the stock in a research report on Thursday, February 13th. Weiss Ratings reaffirmed a "sell (e+)" rating on shares of 10x Genomics in a research report on Tuesday, April 8th. Barclays dropped their price target on 10x Genomics from $15.00 to $12.00 and set an "overweight" rating on the stock in a research note on Thursday, April 10th. Finally, Leerink Partners cut 10x Genomics from an "outperform" rating to a "market perform" rating and reduced their price objective for the company from $25.00 to $12.00 in a research note on Thursday, February 13th. One analyst has rated the stock with a sell rating, nine have given a hold rating and seven have issued a buy rating to the company's stock. According to data from MarketBeat, 10x Genomics currently has a consensus rating of "Hold" and an average target price of $19.79.

10x Genomics Stock Down 1.3 %

TXG stock traded down $0.11 during midday trading on Tuesday, hitting $8.16. The company's stock had a trading volume of 3,053,746 shares, compared to its average volume of 2,180,984. 10x Genomics, Inc. has a 1 year low of $6.78 and a 1 year high of $32.18. The stock has a market cap of $997.98 million, a price-to-earnings ratio of -5.37 and a beta of 2.01. The stock's 50-day moving average price is $10.18 and its 200 day moving average price is $13.76.

10x Genomics (NASDAQ:TXG - Get Free Report) last issued its quarterly earnings results on Wednesday, February 12th. The company reported ($0.40) earnings per share for the quarter, missing analysts' consensus estimates of ($0.32) by ($0.08). 10x Genomics had a negative return on equity of 25.40% and a negative net margin of 29.90%. As a group, equities analysts forecast that 10x Genomics, Inc. will post -1.43 earnings per share for the current fiscal year.

10x Genomics Profile

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.